Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DVAX 
Dynavax Technologies Corporation (DVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: DVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.8
1 Year Target Price $22.8
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.11% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.16B USD | Price to earnings Ratio - | 1Y Target Price 22.8 |
Price to earnings Ratio - | 1Y Target Price 22.8 | ||
Volume (30-day avg) 4 | Beta 1.13 | 52 Weeks Range 9.20 - 14.63 | Updated Date 10/15/2025 |
52 Weeks Range 9.20 - 14.63 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.67% | Operating Margin (TTM) 17.45% |
Management Effectiveness
Return on Assets (TTM) 0.52% | Return on Equity (TTM) -9.28% |
Valuation
Trailing PE - | Forward PE 29.24 | Enterprise Value 856170568 | Price to Sales(TTM) 3.68 |
Enterprise Value 856170568 | Price to Sales(TTM) 3.68 | ||
Enterprise Value to Revenue 2.71 | Enterprise Value to EBITDA 30.92 | Shares Outstanding 117267482 | Shares Floating 100973165 |
Shares Outstanding 117267482 | Shares Floating 100973165 | ||
Percent Insiders 0.6 | Percent Institutions 97.99 |
Upturn AI SWOT
Dynavax Technologies Corporation
Company Overview
History and Background
Dynavax Technologies Corporation was founded in 1996. It initially focused on developing immunostimulatory sequence (ISS) oligonucleotides. Its major milestones include the development and FDA approval of HEPLISAV-B, a hepatitis B vaccine.
Core Business Areas
- Hepatitis B Vaccine: This segment focuses on the development, manufacture, and commercialization of HEPLISAV-B, a hepatitis B vaccine for adults.
- CpG 1018 Adjuvant: This segment involves the development and commercialization of CpG 1018 adjuvant, used in vaccines to enhance immune responses. Including collaborations with Valneva and Clover Biopharmaceuticals.
Leadership and Structure
Ryan Spencer serves as the Chief Executive Officer. The organizational structure consists of various departments including R&D, Commercial Operations, Manufacturing, and Finance.
Top Products and Market Share
Key Offerings
- HEPLISAV-B: HEPLISAV-B is a hepatitis B vaccine for adults. Market share estimates vary, but HEPLISAV-B is gaining significant traction, with competitors including GlaxoSmithKline's Engerix-B and Merck's Recombivax HB. HEPLISAV-B Revenue (2023) : $186.1 Million.
- CpG 1018 Adjuvant: CpG 1018 adjuvant is a key component used in several vaccines including Valneva's IXCHIQ and Clover Biopharmaceuticals SCB-2019. Revenue for 2023 of CpG 1018 was $56.2 million. This is a new market that is constantly changing.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing demand for innovative vaccines and therapeutics.
Positioning
Dynavax is positioned as a specialized vaccine company, with a competitive advantage in hepatitis B vaccination due to the efficacy and convenience of HEPLISAV-B and its successful adjuvant platform.
Total Addressable Market (TAM)
The global hepatitis B vaccine market is estimated to be in the billions of dollars. The adjuvant market is also expanding. Dynavax is positioning itself to capitalize on these markets through HEPLISAV-B and its adjuvant technology.
Upturn SWOT Analysis
Strengths
- HEPLISAV-B's superior efficacy and convenience
- Proprietary CpG 1018 adjuvant platform
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Competition from established pharmaceutical companies
- Fluctuations in vaccine demand
- Sales team is new
Opportunities
- Expanding HEPLISAV-B market share
- Partnering with other companies to utilize CpG 1018 adjuvant
- Developing new vaccines and therapeutics
- Geographic expansion
Threats
- Regulatory changes
- Development of competing vaccines
- Patent expirations
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- GSK (GSK)
- MRK (MRK)
- VRNA (VRNA)
Competitive Landscape
Dynavax is focused on vaccines and adjuvants, holding a strong position with HEPLISAV-B against major players like GSK and Merck. Dynavax has a novel adjuvant technology. There is an increased focused on novel vaccines.
Major Acquisitions
Austrianova
- Year: 2023
- Acquisition Price (USD millions): 34
- Strategic Rationale: Expanding into cell therapy and bioproduction by acquiring a cell encapsulation company.
Growth Trajectory and Initiatives
Historical Growth: Dynavax has experienced significant revenue growth over the past few years driven by HEPLISAV-B.
Future Projections: Analysts project continued revenue growth for Dynavax, driven by increased HEPLISAV-B sales and successful partnerships for CpG 1018 adjuvant.
Recent Initiatives: Recent initiatives include expanding the sales force for HEPLISAV-B and partnering with other companies for CpG 1018 adjuvant development.
Summary
Dynavax is in a strong position driven by HEPLISAV-B and adjuvant technology, showing revenue growth and strategic acquisitions. However, they need to manage competition from larger pharmaceutical companies and diversify their product portfolio. Strategic collaborations look promising. A recent acquisition might boost growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Dynavax Technologies Corporation SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dynavax Technologies Corporation
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2004-02-19 | CEO & Director Mr. Ryan Spencer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 405 | Website https://www.dynavax.com |
Full time employees 405 | Website https://www.dynavax.com | ||
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.